[1] |
Zhao L, Chen S, Yang P, et al. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft⁃versus⁃host disease[J]. Stem Cell Res Ther, 2019,10(1):182. doi: 10.1186/s13287⁃019⁃1287⁃9.
|
[2] |
Yun CW, Lee SH. Potential and therapeutic efficacy of cell⁃based therapy using mesenchymal stem cells for acute/chronic kidney disease[J]. Int J Mol Sci, 2019,20(7):1619. doi: 10. 3390/ijms20071619.
|
[3] |
Päth G, Perakakis N, Mantzoros CS, et al. Stem cells in the treatment of diabetes mellitus ⁃ focus on mesenchymal stem cells[J]. Metabolism, 2019,90:1⁃15. doi: 10.1016/j.metabol.2018.10. 005.
|
[4] |
Wang D, Li J, Zhang Y, et al. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study[J]. Arthritis Res Ther, 2014,16(2):R79. doi: 10.1186/ar4520.
|
[5] |
Wang L, Huang S, Li S, et al. Efficacy and safety of umbilical cord mesenchymal stem cell therapy for rheumatoid arthritis patients: a prospective phase I/II study[J]. Drug Des Devel Ther, 2019,13:4331⁃4340. doi: 10.2147/DDDT.S225613.
|
[6] |
Chen H, Niu JW, Ning HM, et al. Treatment of psoriasis with mesenchymal stem cells[J]. Am J Med, 2016,129(3):e13⁃e14. doi: 10.1016/j.amjmed.2015.11.001.
|
[7] |
Seetharaman R, Mahmood A, Kshatriya P, et al. Mesenchymal stem cell conditioned media ameliorate psoriasis vulgaris: a case study[J]. Case Rep Dermatol Med, 2019,2019:8309103. doi: 10.1155/2019/8309103.
|
[8] |
De Jesus MM, Santiago JS, Trinidad CV, et al. Autologous adipose⁃derived mesenchymal stromal cells for the treatment of psoriasis vulgaris and psoriatic arthritis: a case report[J]. Cell Transplant, 2016,25(11):2063⁃2069. doi: 10.3727/096368916X 691998.
|
[9] |
杨莹, 李政楠, 王秀娟, 等. 脐带来源间充质干细胞的免疫抑制功能研究[J]. 药物评价研究, 2020,43(12):2385⁃2389. doi: 10.7501/j.issn.1674⁃6376.2020.12.005.
|
[10] |
van der Fits L, Mourits S, Voerman JS, et al. Imiquimod⁃induced psoriasis⁃like skin inflammation in mice is mediated via the IL⁃23/IL⁃17 axis[J]. J Immunol, 2009,182(9):5836⁃5845. doi: 10. 4049/jimmunol.0802999.
|
[11] |
Campanati A, Consales V, Orciani M, et al. Role of mesenchymal stem cells in the pathogenesis of psoriasis: current perspectives[J]. Psoriasis (Auckl), 2017,7:73⁃85. doi: 10.2147/PTT.S108311.
|
[12] |
Wang Q, Yang Q, Wang Z, et al. Comparative analysis of human mesenchymal stem cells from fetal⁃bone marrow, adipose tissue, and Warton′s jelly as sources of cell immunomodulatory therapy[J]. Hum Vaccin Immunother, 2016,12(1):85⁃96. doi: 10.1080/21645515.2015.1030549.
|
[13] |
Bonfield TL, Nolan Koloze MT, Lennon DP, et al. Defining human mesenchymal stem cell efficacy in vivo[J]. J Inflamm (Lond), 2010,7:51. doi: 10.1186/1476⁃9255⁃7⁃51.
|
[14] |
Shin TH, Kim HS, Choi SW, et al. Mesenchymal stem cell therapy for inflammatory skin diseases: clinical potential and mode of action[J]. Int J Mol Sci, 2017,18(2):244. doi: 10.3390/ijms18020244.
|
[15] |
王燕芹, 李新新, 薛海波, 等. γ分泌酶抑制剂阻断Notch⁃Hes1信号通路对银屑病样皮炎小鼠γδT17细胞表达的影响[J]. 中华皮肤科杂志, 2019,52(11):801⁃807. doi: 10.35541/cjd. 20190241.
|
[16] |
黄钟洲, 陈小彦, 徐敏, 等. 咪喹莫特诱导的银屑病样小鼠模型的组织学及免疫学特征初步探究[J]. 皮肤性病诊疗学杂志, 2019,26(2):61⁃66. doi: 10.3969/j.issn.1674⁃8468.2019.02. 001.
|
[17] |
Dong C. Seventeen on inflammation[J]. Nat Immunol, 2020,21(8):821⁃822. doi: 10.1038/s41590⁃020⁃0649⁃x.
|
[18] |
Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17⁃producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages[J]. Nat Immunol, 2005,6(11):1123⁃1132. doi: 10.1038/ni1254.
|
[19] |
Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL⁃17+ T helper cells[J]. Cell, 2006,126(6):1121⁃1133. doi: 10.1016/j.cell.2006.07.035.
|
[20] |
Ghoreschi K, Mrowietz U, Röcken M. A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses[J]. J Mol Med (Berl), 2003,81(8):471⁃480. doi: 10.1007/s00109⁃003⁃0460⁃9.
|
[21] |
Szabo SJ, Kim ST, Costa GL, et al. Pillars article: a novel transcription factor, T⁃bet, directs Th1 lineage commitment. Cell. 2000. 100: 655⁃669[J]. J Immunol, 2015,194(7):2961⁃2975.
|
[22] |
Mullen AC, High FA, Hutchins AS, et al. Role of T⁃bet in commitment of TH1 cells before IL⁃12⁃dependent selection[J]. Science, 2001,292(5523):1907⁃1910. doi: 10.1126/science.105 9835.
|
[23] |
Szabo SJ, Sullivan BM, Stemmann C, et al. Distinct effects of T⁃bet in TH1 lineage commitment and IFN⁃gamma production in CD4 and CD8 T cells[J]. Science, 2002,295(5553):338⁃342. doi: 10.1126/science.1065543.
|
[24] |
Sah SK, Park KH, Yun CO, et al. Effects of human mesenchymal stem cells transduced with superoxide dismutase on imiquimod⁃induced psoriasis⁃like skin inflammation in mice[J]. Antioxid Redox Signal, 2016,24(5):233⁃248. doi: 10.1089/ars.2015.6368.
|
[25] |
Ghannam S, Pène J, Moquet⁃Torcy G, et al. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype[J]. J Immunol, 2010,185(1):302⁃312. doi: 10.4049/jimmunol.0902007.
|
[26] |
Liu C, Liu H, Lu C, et al. Kaempferol attenuates imiquimod⁃induced psoriatic skin inflammation in a mouse model[J]. Clin Exp Immunol, 2019,198(3):403⁃415. doi: 10.1111/cei.13363.
|
[27] |
Krueger JG, Wharton KA Jr, Schlitt T, et al. IL⁃17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis[J]. J Allergy Clin Immunol, 2019,144(3):750⁃763. doi: 10.1016/j.jaci.2019.04.029.
|
[28] |
Solberg SM, Sandvik LF, Eidsheim M, et al. Serum cytokine measurements and biological therapy of psoriasis ⁃ prospects for personalized treatment?[J]. Scand J Immunol, 2018,88(6):e12725. doi: 10.1111/sji.12725.
|
[29] |
张莉, 陈利红, 李霞, 等. IL⁃17A单克隆抗体治疗诱导期对寻常性银屑病患者血清细胞因子的影响[J]. 中国皮肤性病学杂志, 2020,34(11):1249⁃1254. doi: 10.13735/j.cjdv.1001⁃7089. 202002067.
|
[30] |
Haider AS, Cohen J, Fei J, et al. Insights into gene modulation by therapeutic TNF and IFNgamma antibodies: TNF regulates IFNgamma production by T cells and TNF⁃regulated genes linked to psoriasis transcriptome[J]. J Invest Dermatol, 2008,128(3):655⁃666. doi: 10.1038/sj.jid.5701064.
|
[31] |
Lowes MA, Chamian F, Abello MV, et al. Increase in TNF⁃alpha and inducible nitric oxide synthase⁃expressing dendritic cells in psoriasis and reduction with efalizumab (anti⁃CD11a)[J]. Proc Natl Acad Sci U S A, 2005,102(52):19057⁃19062. doi: 10.1073/pnas.0509736102.
|
[32] |
Grine L, Dejager L, Libert C, et al. An inflammatory triangle in psoriasis: TNF, type I IFNs and IL⁃17[J]. Cytokine Growth Factor Rev, 2015,26(1):25⁃33. doi: 10.1016/j.cytogfr.2014.10. 009.
|